Literature DB >> 30928412

Neutral sphingomyelinase increases and delocalizes in the absence of Toll-Like Receptor 4: A new insight for MPTP neurotoxicity.

Elisabetta Albi1, Samuela Cataldi1, Michela Codini1, Giuseppina Mariucci1, Andrea Lazzarini2, Maria Rachele Ceccarini1, Ivana Ferri3, Maria Elena Laurenti3, Cataldo Arcuri4, Federica Patria1, Tommaso Beccari1, Carmela Conte5.   

Abstract

Both sphingomyelinase and Toll-Like Receptor 4 (TLR4) are implicated in neurodegenerative diseases. However, the relationship between the two molecules remains unclear. In this study, using WT and TLR4-deficient mice, treated or not with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), we aimed to investigate the relation between TLR4 and neutral sphingomyelinase (nSMase) in the midbrain. We found that the lack of TLR4 caused increase in nSMase protein expression and enzyme activity in the midbrain, as well as a marked delocalization from the cell membranes. This provoked a decrease in sphingomyelin (SM) species and an increase in ceramide levels. We found that exposure of TLR4-deficient mice to MPTP reduces unsaturated SM species by increasing saturated/unsaturated SM ratio. Saturated fatty acid make SM more rigid and could contribute to reducing neural plasticity. In this study we showed that the absence of TLR4 also induced reduction of both heavy neurofilaments and glial fibrillary acidic protein (GFAP) and mice exhibited higher sensitivity to MPTP administration. We speculated about the possible association between nSMase-TLR4 complex and MPTP midbrain damage. Taken together, our findings provide for the first time indications about the role of TLR4 in change of SM metabolism in MPTP neurotoxicity.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Glial fibrillary protein; Neurofilaments; Neutral sphingomyelinase; Toll-Like Receptor 4

Mesh:

Substances:

Year:  2019        PMID: 30928412     DOI: 10.1016/j.prostaglandins.2019.03.004

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  5 in total

Review 1.  Exploring Sphingolipid Implications in Neurodegeneration.

Authors:  Alice V Alessenko; Elisabetta Albi
Journal:  Front Neurol       Date:  2020-05-21       Impact factor: 4.003

Review 2.  Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update.

Authors:  Noha A Gouda; Ahmed Elkamhawy; Jungsook Cho
Journal:  Biomedicines       Date:  2022-02-03

3.  Alterations of Sphingolipid and Phospholipid Pathways and Ornithine Level in the Plasma as Biomarkers of Parkinson's Disease.

Authors:  Kuo-Hsuan Chang; Mei-Ling Cheng; Hsiang-Yu Tang; Cheng-Yu Huang; Hsiu-Chuan Wu; Chiung-Mei Chen
Journal:  Cells       Date:  2022-01-24       Impact factor: 6.600

4.  In Vitro Anti-Inflammatory Effects of Phenolic Compounds from Moraiolo Virgin Olive Oil (MVOO) in Brain Cells via Regulating the TLR4/NLRP3 Axis.

Authors:  Agnese Taticchi; Stefania Urbani; Elisabetta Albi; Maurizio Servili; Michela Codini; Giovanna Traina; Stefania Balloni; Federica Filomena Patria; Luana Perioli; Tommaso Beccari; Carmela Conte
Journal:  Molecules       Date:  2019-12-10       Impact factor: 4.411

Review 5.  Ceramide Metabolism and Parkinson's Disease-Therapeutic Targets.

Authors:  Antía Custodia; Marta Aramburu-Núñez; Clara Correa-Paz; Adrián Posado-Fernández; Ana Gómez-Larrauri; José Castillo; Antonio Gómez-Muñoz; Tomás Sobrino; Alberto Ouro
Journal:  Biomolecules       Date:  2021-06-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.